US-based Guardant Health has entered a partnership with Bayshore HealthCare, a Canadian healthcare services firm, to provide its precision oncology tests across Canada.
The collaboration aims to enhance cancer care by offering advanced testing through Bayshore’s extensive network of clinics.
It will focus on improving the quality of life for Canadians by providing access to advanced cancer diagnostics.
Bayshore HealthCare offers home and community healthcare services to more than 350,000 clients through its 80+ home care offices, 11 pharmacies, and 100+ community care clinics.
The partnership will allow Bayshore to offer advanced cancer testing tools, significantly expanding access for its healthcare providers and patients.
Bayshore clinics will offer Guardant360 tests for therapy selection in advanced cancer.
Bayshore Specialty Rx divisional director Karl Frank said: “Providing customised care plans for our clients is central to Bayshore Healthcare’s mission.
“This partnership will enable our healthcare providers to utilise Guardant’s precision oncology testing to help detect cancer earlier, develop a targeted treatment program for each individual, and better monitor each patient’s response to therapy.”
Established in 2012, Guardant Health is a precision oncology company dedicated to transforming patient care and accelerating cancer therapies.
The company provides insights through advanced blood and tissue tests, real-world data, and AI analytics to guard wellness and extend the time individuals can live free from cancer.
Guardant Reveal blood tests for minimal residual disease detection and recurrence monitoring in early-stage cancer, and Shield blood tests for colorectal cancer screening.
The tests are designed to improve outcomes across all stages of cancer care.
Guardant chairman and co-CEO Helmy Eltoukhy said: “Guardant Health is proud to partner with Bayshore HealthCare in fulfilling their mission to provide better outcomes for patients.
“This partnership will give their physicians access to the latest molecular profiling technology to provide a more complete view of cancer, helping them to develop optimal personalised care plans for their patients, improve outcomes and reduce the number of lives lost to cancer.”
